Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$31.20-3.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Arcutis Biotherapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	160.67M
EPS	—	0.252
FY 2026 · Annual
Revenue	$525M–$540M	538.56M
Revenue (anticipate)	$480M–$495M	—
EPS	—	0.48
FY 2027 · Annual
Revenue	—	695.69M
EPS	—	1.313

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve operating income from -$9.1M in 2026-Q1	The company is working to improve its operating income after a recent loss.	Improving	Operating income remains negative or worsens through FY26	Operating income: $16.429M FY2026-Q2; GAAP. Published target: Operating income improves toward breakeven or positive by FY26 end. Target period is not explicitly aligned with this observation. Source published Aug 5, 202616,429,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6afc2718-1604-426d-bc95-3ef333b0cd76. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve 2026 revenue of $480M-$495M	A primary condition in Arcutis Biotherapeutics, Inc.'s published investment case. The stated target is ~$487.5M.	Intact	Revenue falls below $480M in FY26	Revenue: $129.861M FY2026-Q2; GAAP. Published target: ~$487.5M. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026129,861,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6afc2718-1604-426d-bc95-3ef333b0cd76. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Sustain growth momentum of ZORYVE dermatology drug	Its dermatology drug ZORYVE is driving sales growth.	Intact	ZORYVE sales decline or stall in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.31

$1.13 → $1.31 · observed estimates

FY2027 revenue$0.70B

$0.65B → $0.70B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.13	$647,230,370	6 / 8
2026-07-25	$1.13	$647,230,370	6 / 8
2026-07-26	$1.13	$647,230,370	6 / 8
2026-07-27	$1.08	$647,092,866	5 / 6
2026-07-28	$1.13	$647,230,370	6 / 8
2026-07-29	$1.13	$647,230,370	6 / 8
2026-07-30	$1.13	$647,230,370	6 / 8
2026-07-31	$1.13	$647,230,370	6 / 8
2026-08-01	$1.13	$647,230,370	6 / 8
2026-08-02	$1.13	$647,230,370	6 / 8
2026-08-03	$1.13	$647,230,370	6 / 8
2026-08-04	$1.08	$647,092,866	5 / 6
2026-08-05	$1.13	$647,230,370	6 / 8
2026-08-06	$1.13	$647,230,370	6 / 8
2026-08-07	$1.19	$662,584,587	5 / 6
2026-08-08	$1.24	$671,393,960	6 / 8
2026-08-09	$1.24	$671,393,960	6 / 8
2026-08-10	$1.24	$671,393,960	6 / 8
2026-08-11	$1.30	$685,518,840	6 / 8
2026-08-12	$1.30	$685,518,840	6 / 8
2026-08-13	$1.30	$685,518,840	6 / 8
2026-08-14	$1.19	$662,584,587	5 / 6
2026-08-15	$1.19	$662,584,587	5 / 6
2026-08-16	$1.19	$662,584,587	5 / 6
2026-08-17	$1.19	$662,584,587	5 / 6
2026-08-18	$1.19	$662,584,587	5 / 6
2026-08-19	$1.19	$662,584,587	5 / 6
2026-08-20	$1.19	$662,584,587	5 / 6
2026-08-21	$1.29	$685,518,837	5 / 6
2026-08-22	$1.29	$685,518,837	5 / 6
2026-08-23	$1.29	$685,518,837	5 / 6
2026-08-24	$1.29	$685,518,837	5 / 6
2026-08-25	$1.29	$685,518,837	5 / 6
2026-08-26	$1.29	$685,518,837	5 / 6
2026-08-27	$1.29	$685,518,837	5 / 6
2026-08-28	$1.29	$685,518,837	5 / 6
2026-08-29	$1.29	$685,518,837	5 / 6
2026-08-30	$1.29	$685,518,837	5 / 6
2026-08-31	$1.29	$685,518,837	5 / 6
2026-09-01	$1.29	$685,518,837	5 / 6
2026-09-02	$1.29	$685,518,837	5 / 6
2026-09-03	$1.29	$685,518,837	5 / 6
2026-09-04	$1.29	$685,518,837	5 / 6
2026-09-05	$1.29	$685,518,837	5 / 6
2026-09-06	$1.29	$685,518,837	5 / 6
2026-09-07	$1.29	$685,518,837	5 / 6
2026-09-08	$1.29	$685,518,837	5 / 6
2026-09-09	$1.29	$685,518,837	5 / 6
2026-09-10	$1.29	$685,518,837	5 / 6
2026-09-11	$1.29	$685,518,837	5 / 6
2026-09-12	$1.29	$685,518,837	5 / 6
2026-09-13	$1.29	$685,518,837	5 / 6
2026-09-14	$1.29	$685,518,837	5 / 6
2026-09-15	$1.29	$685,518,837	5 / 6
2026-09-16	$1.29	$685,518,837	5 / 6
2026-09-17	$1.33	$686,921,527	5 / 6
2026-09-18	$1.33	$686,921,527	5 / 6
2026-09-19	Unavailable	$686,921,527	4 / 5
2026-09-20	Unavailable	$686,921,527	4 / 5
2026-09-21	Unavailable	$686,921,527	4 / 5
2026-09-22	Unavailable	$686,921,527	4 / 5
2026-09-23	Unavailable	$686,921,527	4 / 5
2026-09-24	Unavailable	$686,921,527	4 / 5
2026-09-25	Unavailable	$686,921,527	4 / 5
2026-09-26	Unavailable	$686,921,527	4 / 5
2026-09-27	Unavailable	$686,921,527	4 / 5
2026-09-28	Unavailable	$686,921,527	4 / 5
2026-09-29	Unavailable	$686,921,527	4 / 5
2026-09-30	Unavailable	$686,921,527	4 / 5
2026-10-01	Unavailable	$686,921,527	4 / 5
2026-10-02	Unavailable	$686,921,527	4 / 5
2026-10-03	Unavailable	$686,921,527	4 / 5
2026-10-04	Unavailable	$686,921,527	4 / 5
2026-10-05	Unavailable	$686,921,527	4 / 5
2026-10-06	Unavailable	$686,921,527	4 / 5
2026-10-07	Unavailable	$686,921,527	4 / 5
2026-10-08	Unavailable	$686,921,527	4 / 5
2026-10-09	Unavailable	$686,921,527	4 / 5
2026-10-10	Unavailable	$686,921,527	4 / 5
2026-10-11	Unavailable	$686,921,527	4 / 5
2026-10-12	Unavailable	$686,921,527	4 / 5
2026-10-13	Unavailable	$686,921,527	4 / 5
2026-10-14	Unavailable	$686,921,527	4 / 5
2026-10-15	Unavailable	$686,921,527	4 / 5
2026-10-16	Unavailable	$686,921,527	4 / 5
2026-10-17	Unavailable	$686,921,527	4 / 5
2026-10-18	$1.26	$686,804,336	5 / 6
2026-10-19	$1.26	$686,804,336	5 / 6
2026-10-20	$1.26	$686,804,336	5 / 6
2026-10-21	$1.31	$695,691,837	5 / 6
2026-10-22	$1.31	$695,691,837	5 / 6
2026-10-23	$1.31	$695,691,837	5 / 6
2026-10-24	$1.31	$695,691,837	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimOct 19 · prior Aug 6

$38.00 → $44.00+15.8%

Cantor FitzgeraldOct 15

$48.00New observation · no comparable prior

JefferiesOct 8

$39.00New observation · no comparable prior

$0$26.40$52.80

1 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve operating income from -$9.1M in 2026-Q1Operating income: $16.429M
Achieve 2026 revenue of $480M-$495MRevenue: $129.861M
Sustain growth momentum of ZORYVE dermatology drugDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-37.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Arcutis Biotherapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-growth, loss-making commercial-stage drug company, not a proven durable compounder. The long-term thesis is intact: recent results are strong and management is advancing ZORYVE, though confidence is medium and risks remain elevated.

What's priced into Arcutis Biotherapeutics, Inc.

The valuation signal is described as justified, with no fragility flags, but its confidence is low. The expectations gap is negative, suggesting expectations may be demanding; the valuation score also fell sharply and the signal softened to mildly favorable.

What the fundamentals likely do

Near term, the main test is delivering the raised 2026 net product sales guidance of $525 million to $540 million. Revenue grew 59% year over year in 2026 Q2, and the dermatology sales force expansion is complete, with primary care and pediatric team-building underway. ARQT remains loss-making, and a guidance cut or weakening economic data could pressure execution and confidence.

What Arcutis Biotherapeutics, Inc. hinges on

The multi-year view hinges on continued ZORYVE growth and progress expanding its uses, including regulatory and clinical work. Near term, meeting raised guidance is important; reversing that guidance could damage management credibility. Healthcare-sector momentum may help if major peers keep reporting strong results, while weaker employment data could add concern.